Clinical outcomes are complex and often involve multiple systemic burdens. Early identification and standardized diagnosis are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical outcomes, imaging inspections, laboratory tests and pathological activation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment plans. Treatment plans for treatment and management of dry lymphoma syndrome require individual development, typically including multidimensional management such as drug therapy, rehabilitation, and regular follow-up. In recent years, with the development of treatment-oriented, immune-regulatory treatments and precision medicine, many autoimmune and rheumatic immune diseases that were previously difficult to treat have been significantly improved.
Treatment requires close monitoring of therapeutic effects and adverse reactions, adapting to timely regimens according to changes in conditions. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of lymphomas associated with dry syndrome. The platform serves the China International Medical Service System, a team of domestically authoritative experts in the field of autoimmune and rheumatic immunity, to provide the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.